# Hechen Bioworkx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hechen-bioworkx

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.hcbioworkx.com
- Total disclosed funding: $15M
- Latest round: Series A (May 7, 2026)
- Investors on record: 6

## About

Established in 2022 by co-founder Xie Xixian and based in Hefei, China, Hefei Hechen Biotechnology is a synthetic biology company focusing on the development and industrialization of functional active ingredients. is a synthetic biology company focusing on the development and industrialization of functional active ingredients. The core team members of the company are from Unilever, Coca-Cola and other companies as well as Tianjin University of Science and Technology and other institutions. Among them, the company's CTO, Dr. Weizheng Zhou, is an expert in the formulation and application of functional active ingredients and was the head of Unilever's Strategic Science Research Department in China. As of June 2026 Yu Hongjian is the CEO of the comapny. In May 2026, Hechen Bioworkx raised CNY 100 million in series A funding from Anhui Venture Investment, Changxing Fund, Guoyuan Equity Investment, Jiansu Capital and Shikexincai.

The company mainly focuses on strain technology development and industrialization application of synthetic organisms, and has now completed the construction of three platforms: SynBio Agile Development System, Highly Effective Active Ingredients Delivery and Agile BioFabrication. The core product built with the platform is L-Ergothioneine (EGT), an engineered bacterium that can effectively protect against UV damage and meet the needs of different application scenarios such as food, medicine and cosmetics.

The company's revenue is generated through the development and industrialization of functional active ingredients.

The company plans to use the May 2026 funding to build a production facility and apply artificial intelligence to enhance its synthetic biology and chemistry platform, supporting research and scaling of biomanufacturing.

## Funding rounds

- Series A, May 7, 2026, $15M — Jiansu Capital, Guoyuan Equity Investment, Shikexincai
- Angel, Dec 31, 2022 — Huaige Capital, Hongbo Capital, Guoyuan Innovation Investment
- Angel, Oct 10, 2022 — Huaige Capital

## Investors

- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Angel
- Hongbo Capital — Angel
- Guoyuan Innovation Investment — Angel
- Jiansu Capital — Series A
- Guoyuan Equity Investment (https://capitalatlas.ai/funds/guoyuan-equity-investment) — Series A
- Shikexincai — Series A